Frontier Medicines Presents New Preclinical Data on its Development Candidate, FMC-376, a Dual KRASG12C Inhibitor, at the 2023 AACR Annual Meeting
16 avr. 2023 15h00 HE
|
Frontier Medicines
-FMC-376 is a highly selective, direct dual inhibitor designed to rapidly and completely block both the active and inactive forms of KRASG12C and overcome the limitations seen with single-acting...
Frontier Medicines to Spotlight Lead Candidate, Novel Dual KRASG12C Inhibitor FMC-376, and the Frontier™ Platform at the 2023 AACR Annual Meeting
14 mars 2023 17h56 HE
|
Frontier Medicines
BOSTON and SOUTH SAN FRANCISCO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance breakthrough...
Frontier Medicines Expands Leadership Team with Addition of Christo Shalish as Head of Business Development
28 févr. 2023 08h00 HE
|
Frontier Medicines
BOSTON and SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance breakthrough...
Frontier Medicines Advances First Development Candidate, FMC-376, a Uniquely Differentiated Inhibitor of Both Active and Inactive KRASG12C, into IND-Enabling Studies
05 janv. 2023 07h30 HE
|
Frontier Medicines
FMC-376 directly, rapidly, and completely blocks both active and inactive forms of KRASG12C to overcome non-response and resistance seen with prior generation KRASG12C inhibitors The company has...
Frontier Medicines Announces Advancement of Second and Third Programs Under Global Partnership with AbbVie
05 janv. 2023 07h00 HE
|
Frontier Medicines
SOUTH SAN FRANCISCO, Calif. and BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance breakthroughs against...
Frontier Medicines to Present at the 41st Annual J.P. Morgan Healthcare Conference
04 janv. 2023 08h00 HE
|
Frontier Medicines
SOUTH SAN FRANCISCO, Calif. and BOSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a precision medicine company advancing transformative drugs against historically undruggable...
Frontier Medicines Announces Appointment of Accomplished Finance and Operations Executive, Setareh “SiSi” Pouraghabagher, to Board of Directors
08 nov. 2022 08h00 HE
|
Frontier Medicines
BOSTON and SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance breakthrough...
Frontier Medicines to Present at Credit Suisse 31st Annual Healthcare Conference
01 nov. 2022 08h00 HE
|
Frontier Medicines
BOSTON and SOUTH SAN FRANCISCO, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance breakthrough...
Frontier Medicines Announces the Appointment of Seasoned Legal Executive Mark Dizon, J.D., as General Counsel
25 août 2022 08h00 HE
|
Frontier Medicines
SOUTH SAN FRANCISCO, Calif., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance breakthrough therapies against...
Frontier Medicines Announces Distinguished Oncologist Dr. Pasi Jänne Joins its Scientific Advisory Board
14 juil. 2022 08h00 HE
|
Frontier Medicines
SOUTH SAN FRANCISCO, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance breakthrough therapies against...